

UCLA

UCLA Previously Published Works

Title

Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors

Permalink

<https://escholarship.org/uc/item/8kp9t5fk>

Journal

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(8)

ISSN

0305-7453

Authors

Bakal, DR
Coelho, LE
Luz, PM
[et al.](#)

Publication Date

2018-08-01

DOI

10.1093/jac/dky145

Peer reviewed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors

Running Title: Obesity following ART initiation

David R. BAKAL^{1*}, Lara E. COELHO², Paula M. LUZ², Jesse L. CLARK¹, Raquel B. DE BONI², Sandra W. CARDOSO², Valdilea G. VELOSO², Jordan E. LAKE^{1,3†} and Beatriz GRINSZTEJN^{2†}

¹Department of Medicine, University of California Los Angeles David Geffen School of Medicine, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.

²Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Av. Brasil, 4365 - Manguinhos, Rio de Janeiro - RJ, Brazil.

³Department of Medicine, The University of Texas Health Science Center at Houston (UTHealth) McGovern Medical School, 6431 Fannin St, Houston, TX 77030, USA.

[†] Co-senior authors

*Corresponding Author: David Bakal
Email: dbakal89@gmail.com
Telephone: (510) 220-0834

40 **Abstract**

41 **Introduction**

42 Obesity rates are increasing among HIV-infected individuals, but risk factors for obesity development on
43 ART remain unclear. In a cohort of HIV-infected adults in Rio de Janeiro, Brazil, we aimed to determine
44 obesity rates before and after ART initiation, and to analyze risk factors for incident obesity on ART.

45 **Materials and methods**

46 We retrospectively analyzed data from individuals initiating ART between 2000 and 2015. BMI was
47 calculated at baseline (time of ART initiation). Participants who were non-obese at baseline and had ≥ 90
48 days of ART exposure were followed until the development of obesity or the end of follow-up. Obesity
49 incidence rates were estimated using Poisson regression models and risk factors were assessed using Cox
50 regression models.

51 **Results**

52 Of participants analyzed at baseline (n=1,794), 61.3% were male, 48.3% were white, and 7.9% were
53 obese. Among participants followed longitudinally (n=1,567), 66.2% primarily used a NNRTI, 32.9% a PI
54 and 0.9% an integrase inhibitor (INSTI); 18.3% developed obesity, and obesity incidence was 37.4 per
55 1000 person-years. In multivariable analysis, the greatest risk factor for developing obesity was the use of
56 an INSTI as the primary ART core drug (adjusted hazard ratio 7.12, $p < 0.0001$); other risk factors included
57 younger age, female sex, higher baseline BMI, lower baseline CD4⁺ T lymphocyte count, higher baseline
58 HIV-1 RNA, hypertension, and diabetes mellitus.

59 **Discussion**

60 Obesity following ART initiation is frequent among HIV-infected adults; key risk factors include female
61 sex, HIV disease severity and INSTI use. Further research regarding the association between INSTIs and
62 the development of obesity is needed.

63

64

65Introduction

66Advancements in ART have led to vast improvements in the general health and life expectancy of HIV-
67infected individuals.¹⁻³ Among individuals on suppressive ART, wasting has become less common, and
68recent studies from both upper- and lower-income countries report weight gain irrespective of ART type.<sup>4-
69⁸ Additionally, many countries have reported an increasing prevalence of overweight and obese states in
70HIV-infected persons even prior to ART initiation, consistent with trends in the general population.^{6,9} As
71obesity rates rise, so does the risk for obesity-related complications.¹⁰⁻¹³ This is particularly worrisome as,
72even in the absence of obesity, HIV-infected individuals are already at high risk of non-AIDS events such
73as cardiovascular and fatty liver disease.¹⁴⁻¹⁶</sup>

74 Among HIV-infected individuals initiating ART, female sex,^{4,17} lower baseline CD4⁺ T
75lymphocyte counts^{4,17,18} and a lower baseline BMI^{4,6} have been associated with subsequent weight gain.
76However, associations between specific ART regimens and weight gain/obesity remain controversial.^{5,17-19}

77 In a large cohort of HIV-infected, ART-treated adults in Rio de Janeiro, Brazil, we aimed to
78calculate the prevalence of obesity prior to ART initiation and the incidence of obesity after ART
79initiation. Additionally, we aimed to determine specific risk factors associated with the development of
80obesity after ART initiation, including associations between weight gain and the use of specific ART
81drugs and classes.

82

83Materials and methods

84Ethics

85This study was approved by the ethics committee of the Evandro Chagas Clinical Research Institute of the
86Oswaldo Cruz Foundation (INI/FIOCRUZ, CAAE 0032.0.009.000-10) and was conducted according to
87the principles expressed in the Declaration of Helsinki. All patient records/information was de-identified
88prior to analysis. The study was exempt from additional review by the Office of the Human Research
89Protection Program of the University of California, Los Angeles.

90Study population

91The HIV clinical cohort of INI/FIOCRUZ in Rio de Janeiro, Brazil includes a database of socio-
92demographic and clinical information on patients receiving HIV care. Trained extractors input
93information from medical records and laboratory results into the database biannually. Complete
94procedures regarding cohort data collection have been described elsewhere.²⁰

95**Inclusion and exclusion criteria**

96Participants included in the baseline obesity prevalence analysis were HIV-infected adults ≥ 18 years of
97age who started their first ART regimen between January 1, 2000 and December 31, 2015. Women who
98became pregnant while on ART were excluded. In addition, participants without height data and without a
99weight recorded within 180 days prior to and 30 days after ART initiation were excluded. For participants
100with multiple eligible height and weight records, the height/weight recorded closest to the date of ART
101initiation was used to calculate the baseline BMI (defined as weight in kilograms divided by the square of
102height in meters). Participants from the baseline obesity prevalence analysis were included in the
103longitudinal obesity incidence analysis if they were non-obese ($\text{BMI} < 30 \text{ kg/m}^2$) at the time of ART
104initiation and had ≥ 90 days of cumulative exposure to at least one NRTI and at least one ART core drug
105class (NNRTI, PI, or integrase strand transfer inhibitor [INSTI]).

106**Study design**

107In this retrospective cohort study, participants included in the baseline analysis were assessed for the
108presence of obesity ($\text{BMI} \geq 30 \text{ kg/m}^2$) prior to ART initiation. Participants included in the longitudinal
109analysis were retrospectively followed for the development of obesity after ART initiation. In order to
110determine whether a participant developed obesity, all recorded weights after baseline and prior to
111December 31, 2015 were compiled into a list and the amount of time between sequential weight
112measurements was calculated. Every post-baseline weight was required to have been measured within two
113years of the previously recorded weight in order to be included. Weights that were recorded after a gap of
114greater than two years, and any subsequent measurements, were excluded from the analysis. These data
115were excluded because significant weight changes occurring within these large time intervals could have
116occurred but not been captured, and exclusion ensured that the weights being analyzed provided an
117accurate longitudinal depiction of weight changes over the course of follow-up.

118 Follow-up for each participant started on their date of ART initiation. For participants who
119 developed obesity, follow-up ended on the date of obesity diagnosis. For participants who did not develop
120 obesity, follow-up ended on the date of their last clinic visit, date of death, two years after their last
121 recorded weight measurement, or December 31, 2015, whichever occurred first. Loss to follow-up
122 (LTFU) was defined among participants whose last clinic visit was earlier than any of the above-
123 mentioned dates.

124 Baseline BMI was categorized as underweight ($<18.5 \text{ kg/m}^2$), normal weight ($18.5\text{-}24.9 \text{ kg/m}^2$),
125 overweight ($25\text{-}29.9 \text{ kg/m}^2$) or obese ($\geq 30 \text{ kg/m}^2$). Age at ART initiation was calculated by subtracting the
126 participant's date of birth from their ART start date. Self-reported sex/gender was grouped as "male,"
127 "female," or "transgender woman (TW)." Self-reported race/skin color was categorized as "white,"
128 "black," or "mixed/other." Education was self-reported and dichotomized as 0-8 years or >8 years.
129 Baseline CD4⁺ T lymphocyte count and HIV-1 RNA were defined as the values recorded closest to the
130 date of ART initiation (within 180 days before and 30 days after ART initiation). Time from HIV
131 diagnosis to ART start was calculated by subtracting the participant's date of HIV diagnosis from their
132 ART start date. History of hypertension was defined as any of the following recorded up to 30 days after
133 ART initiation: diagnosis of hypertension, use of antihypertensive medication, systolic blood pressure
134 $>140 \text{ mmHg}$, or diastolic blood pressure $>90 \text{ mmHg}$. History of diabetes mellitus was defined as any of
135 the following recorded up to 30 days after ART initiation: history of diabetes mellitus, diabetes on
136 treatment, fasting glucose level $\geq 126 \text{ mg/dL}$, or hemoglobin A1c $>6.5\%$. History of dyslipidemia was
137 defined as any of the following recorded up to 30 days after ART initiation: history of dyslipidemia, use
138 of lipid-lowering therapy, low-density lipoprotein cholesterol $>159 \text{ mg/dL}$, high-density lipoprotein
139 cholesterol $<40 \text{ mg/dL}$, total cholesterol $>239 \text{ mg/dL}$, or triglycerides $>199 \text{ mg/dL}$. History of an AIDS-
140 defining illness was defined as any of the diagnoses included in the Centers for Disease Control and
141 Prevention 1993 definition diagnosed up to 30 days after ART initiation.²¹ Participants were classified as
142 "ever smoker" if they indicated any smoking history on cross-sectional survey.²² Those missing data from
143 the cross-sectional survey were classified as "ever smoker" if their medical chart indicated a history of
144 tobacco use.

145 The summation of an individual's time on ART during follow-up was calculated for the following
146 drugs/classes: tenofovir, zidovudine, NNRTI, PI and INSTI. Time spent on abacavir was categorized with
147 time on tenofovir, and time on didanosine, zalcitabine and stavudine were categorized with time on
148 zidovudine. This was done due to the low frequency of use of these agents for ≥ 90 days (abacavir n=111,
149 didanosine n=89, zalcitabine n=1, stavudine n=104). Each participant was classified according to the
150 NRTI (tenofovir versus zidovudine) and core drug class (NNRTI versus PI versus INSTI) used for the
151 greatest cumulative time during their follow-up.

152 **Statistical analysis**

153 Descriptive statistics were compared using Chi-squared tests for categorical variables and Kruskal-Wallis
154 tests for continuous variables. Obesity incidence was estimated per 1000 person-years of follow-up
155 (PYFU) using Poisson regression models. Cox competing risk models (accounting for death and LTFU as
156 competing events) were used to assess factors associated with incident obesity after ART initiation.
157 Multivariable modeling was performed by including all covariates with p-value ≤ 0.20 in bivariate models
158 and sequentially removing variables with the highest p-value until only variables with p-value ≤ 0.05
159 remained. Age at ART initiation and most-used NRTI were forced into the final model. Date of ART
160 initiation and end of follow-up date were both accounted for in the final model. Multiple imputation for
161 missing data was performed for missing values of baseline CD4⁺ T lymphocyte count (n=125) and log of
162 HIV-1 RNA (n=229). Continuous variables that were not linearly correlated with obesity (baseline BMI
163 and baseline CD4⁺ T lymphocyte count) were included in the models using restricted cubic splines to
164 relax linearity assumptions.²³ R (version 3.1.1) and libraries "survival", "mi", "rms" and "mstate" were
165 used for the analyses.

166

167 **Results**

168 **Baseline characteristics and obesity prevalence**

169 A total of 1794 individuals met inclusion criteria for the baseline analysis (Figure 1). At the time of ART
170 initiation, 251 participants (14.0%) were underweight, 1012 (56.4%) were normal weight, 390 (21.7%)
171 were overweight and 141 (7.9%) were obese. Median age at ART initiation was 36.3 years (IQR: 29.5-

17244.1). The majority of participants were male, white, and had greater than eight years of schooling.
173Median baseline CD4⁺ T lymphocyte count was 226 cells/mm³ (IQR: 79-350) and the median log HIV-1
174RNA was 4.8 (IQR: 4.0-5.4). Median time from the date of HIV diagnosis to ART initiation was 0.6 years
175(IQR: 0.2-2.7). Participants had the following histories of comorbid disease: 12.9% hypertension, 4.9%
176diabetes mellitus, 27.0% dyslipidemia, 38.8% AIDS-defining illness, and 51.0% ever smoker. The
177prevalence of obesity at ART initiation increased over the study period (4.9% in 2000-2003, 6.2% in
1782004-2007, 6.4% in 2008-2011 and 12.0% in 2012-2015) (Table 1).

179**Factors associated with incident obesity after ART initiation**

180Of the 1794 individuals analyzed at baseline, 1567 were non-obese and had ≥90 days of cumulative
181exposure to at least one NRTI and one core drug class, thus meeting inclusion criteria for the obesity
182incidence analysis. These individuals contributed 7657 PYFU with a median follow-up time of 4.1 years
183(IQR: 2.1-7.0). The median time to obesity diagnosis was 1.9 years (IQR: 0.9-3.6), while the median
184follow-up time for participants who did not develop obesity was 4.7 years (IQR: 2.5-7.4). A total of 1198
185individuals (76.5%) gained weight over the study period, 688 (43.9%) increased their BMI category, and
186286 (18.3%) developed obesity. From baseline to end of study, the median BMI increased from 22.3 to
18724.7 kg/m² (p<0.0001), with a median annual increase of 0.4 kg/m²/year.

188 Table 2 shows longitudinal changes in BMI stratified by baseline BMI. For those underweight at
189baseline, the median BMI increased from 17.1 to 20.3 kg/m², with a median annual increase of 0.6
190kg/m²/year. A total of 65.9% of those underweight at baseline were classified into a higher BMI category
191at study end. For those of normal weight at baseline, the median BMI increased from 21.9 to 24.2 kg/m²,
192with a median annual increase of 0.4 kg/m²/year. A total of 40.3% of those of normal weight at baseline
193were categorized as overweight or obese at study end. For those overweight at baseline, the median BMI
194increased from 26.9 to 28.6 kg/m², with a median annual increase of 0.3 kg/m²/year. A total of 40.0% of
195those overweight at baseline had become obese by the end of follow-up.

196 Table 3 shows characteristics of participants who developed obesity after starting ART compared
197to those who remained non-obese, as well as the unadjusted hazard ratios for incident obesity. Participants
198who became obese were more likely to have the following characteristics: female sex (24.4% females

199developed obesity versus 16.7% males and 13.1% TW, $p=0.0005$), higher baseline BMI (median 25.3
200versus 21.8 kg/m^2 , $p<0.0001$), lower baseline CD4^+ T lymphocyte count (median 152 versus 233
201cells/ mm^3 , $p<0.0001$), higher baseline log HIV-1 RNA (median 5.0 versus 4.8, $p=0.0100$), use of
202zidovudine as the most-used NRTI (zidovudine 21.3% versus tenofovir 16.1%, $p=0.0104$), use of an
203INSTI as the most-used ART core drug class (INSTI 42.9% versus NNRTI 17.3% and PI 19.4%,
204 $p=0.0346$), and a history of hypertension (hypertension 30.1% versus no hypertension 16.8%, $p<0.0001$).
205Of note, all variables listed in Table 3 were considered for inclusion in the final multivariable model.

206 The overall incidence rate of obesity was 37.4 per 1000 PYFU. Patients who were overweight at
207baseline had a higher incidence of obesity (106.6 per 1000 PYFU) than those who were underweight and
208normal weight (5.2 and 25.5 per 1000 PYFU, respectively). Females had a higher incidence of obesity
209(49.8 per 1000 PYFU) compared to males and TW (34.5 and 25.5 per 1000 PYFU, respectively) (Table
2102). In addition, those who started ART between the years 2000-2003 had a lower incidence of obesity
211(20.1 per 1000 PYFU) than those who started ART between 2004-2007, 2008-2011 and 2012-2015 (39.7,
21244.1 and 43.2 per 1000 PYFU, respectively) (Supplementary Table 1).

213 In individuals primarily using an INSTI ($n=14$), obesity incidence was higher than those
214primarily using an NNRTI ($n=1038$) or PI ($n=515$) (incidence of 370.7 versus 36.0 and 37.8 per 1000
215PYFU, respectively). In addition, those using an INSTI as their most-used ART core drug had greater
216annual BMI change versus NNRTI and PI (median gain of 1.6 versus 0.4 and 0.4 $\text{kg}/\text{m}^2/\text{year}$, respectively,
217 $p=0.1569$) and shorter time to obesity diagnosis (median 1.0 versus 1.9 and 1.9 years, respectively,
218 $p=0.1850$). Among those classified under INSTI (10 men, 3 women, 1 TW), obesity incidence was higher
219for women than men (1073.2 versus 344.4 per 1000 PYFU, respectively), and women experienced greater
220annual BMI gain than men (median of 5.0 versus 0.5 kg/m^2 per year) (Supplementary Table 2,
221Supplementary Table 3).

222 In multivariable models accounting for competing risks, the following variables were associated
223with the development of obesity after ART initiation: younger age at ART initiation (adjusted hazard ratio
224[aHR] 0.82 per ten year increase, $p=0.0048$), female sex (aHR 1.66, $p=0.0003$), higher baseline BMI
225(using restricted cubic splines), lower baseline CD4^+ T lymphocyte count (using restricted cubic splines),

226higher baseline HIV-1 RNA (aHR 1.16, p=0.0275), use of an INSTI as the ART core drug (aHR 7.12,
227p<0.0001), and baseline diagnoses of hypertension (aHR 1.54, p=0.0136) and diabetes mellitus (aHR
2281.92, p=0.0238) (Figure 2).

229

230Discussion

231We aimed to characterize obesity rates and risk factors in HIV-infected adults before and after ART
232initiation. We observed that at the time of ART initiation, 7.9% of participants were obese, and this
233prevalence increased over the study period (2000-2015). This trend can likely be attributed to a
234combination of increasing obesity incidence worldwide²⁴ and 2012-2013 international guidelines
235recommending earlier initiation of ART.^{25,26} While the prevalence of obesity at ART initiation observed in
236our cohort was lower than that reported in the Brazilian general population, where the prevalence of
237obesity steadily rose from 11.9% in 2006 to 17.9% in 2014,²⁷ the prevalence of obesity at ART initiation
238increased by calendar year in our cohort, as did the incidence rate of obesity after ART initiation.

239 Among non-obese individuals initiating ART, 18.3% developed obesity with a rapid median time
240of 1.9 years from ART initiation to obesity diagnosis. The greatest risk factor for developing obesity after
241ART initiation was having an INSTI as the most-used ART core drug class. Other risk factors included
242younger age, female sex, higher baseline BMI, lower baseline CD4⁺ T lymphocyte count, higher baseline
243HIV-1 RNA, and baseline diagnoses of hypertension and diabetes mellitus.

244 The observed associations between female sex and weight gain after ART initiation have been
245previously documented.^{5,17} Individuals who were overweight at baseline had a greater risk of developing
246obesity because their starting BMI was closer to the obesity threshold; however, underweight individuals
247had the greatest annual change in BMI. This may be explained in part by the extreme relative immune
248reconstitution that can occur in individuals with more advanced HIV disease after ART initiation.⁴ This
249same explanation can be used to justify associations between obesity development and lower baseline
250CD4⁺ T lymphocyte counts and higher baseline HIV-1 RNA levels. This explanation may also help clarify
251why younger participants were more likely to develop obesity after ART use, as younger participants may
252have more robust immunologic response to ART, making them more susceptible to weight gain. Finally,

253associations between obesity development and baseline hypertension and diabetes mellitus likely results
254from the fact that these conditions were more prevalent in individuals who were overweight at baseline
255compared to those who were of normal weight.

256 Importantly, the greatest risk factor for developing obesity in our cohort was having an INSTI as
257the most-used ART core drug class. Compared to those who primarily used an NNRTI and PI, participants
258who primarily used an INSTI had ten-fold higher obesity incidence, four-fold greater annual BMI gain
259and nearly twice as rapid time to obesity. Of note, females classified under INSTI had remarkably high
260rates of obesity and annual BMI gain. When adjusted for potential confounding, having an INSTI as the
261most-used ART core drug was associated with over seven times the risk of developing obesity. Although
262the sample size of those classified under INSTI was small (n=14), the magnitude of this association is
263impressive and has only recently been described in the literature. Menard *et al* looked at weight changes
264in 462 individuals prescribed dolutegravir plus abacavir/lamivudine or tenofovir/emtricitabine and found
265that after one year of therapy, mean weight gain was 3 kg. This weight gain was significant for women
266and showed a tendency toward significance for men.²⁸ Similarly, Norwood *et al* found that, in individuals
267with ≥ 2 years of exposure to efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC),
268those who were switched to an INSTI-containing regimen (dolutegravir/abacavir/lamivudine or
269raltegravir/TDF/FTC or elvitegravir/cobicistat/TDF/FTC) gained 2.9 kg after 18 months, compared to a
2700.7 kg gain in those switched to a PI-containing regimen and a 0.9 kg gain in those who remained on
271EFV/TDF/FTC.²⁹

272 Potential mechanisms explaining the association between weight gain and INSTI use are
273currently unknown. One possible explanation is that INSTIs cause an especially rapid drop in HIV-1
274RNA,³⁰ and HIV-1 RNA is positively correlated with resting energy expenditure.³¹ Thus, individuals
275taking INSTIs may experience greater short-term decreases in resting energy expenditure, predisposing
276them to weight gain. This hypothesis was unable to be assessed in our cohort as we did not have sufficient
277HIV-1 RNA data post-ART initiation to explore if decreases in HIV-1 RNA correlated with weight gain. A
278second possible explanation is that raltegravir has higher levels of tissue penetration compared to other

279classes of ART,³² which could result in yet unidentified mechanisms of metabolic change that drive weight
280gain.

281 It should be noted that of the 14 individuals who had an INSTI as their most-used ART core drug,
28250% had a baseline diagnosis of tuberculosis compared to 24% in the total cohort. The longitudinal
283multivariable analysis accounted for TB in the variable “History of AIDS defining illness.” When forcing
284TB into the final multivariable analysis, INSTIs were still associated with an increased risk of obesity
285(aHR 5.5, p=0.0002) (Supplementary Table 4). Additionally, when repeating the multivariable analysis in
286exclusively TB-infected individuals (n=383), the association between INSTIs and an increased risk of
287obesity remained (aHR 6.9, p=0.0006) (Supplementary Table 5). Thus, even when adjusting for the
288potential confounding effect of TB, INSTIs were still associated with an increased risk of developing
289obesity.

290 This study has several limitations. First, we did not have data regarding caloric intake, alcohol
291use, menopausal status, concomitant medication usage that may have caused weight changes (i.e.
292metformin, psychiatric medications), or physical activity levels in participants, as would be ideal. Second,
293we were forced to rely on BMI as the sole marker of obesity because we did not have data from other
294anthropomorphic measurements, such as waist circumference and waist-to-hip ratio. Third, since this was
295an observational study, participants did not have weights recorded at regularly scheduled intervals. In
296order to account for this, each participant was screened to ensure that they did not have a period of greater
297than two years where they did not have a weight recorded. Another limitation is that NRTI usage and ART
298core drug usage were classified into mutually exclusive categories. While this categorization allowed for
299the comparison of obesity rates between NRTIs and core drug classes, it could not account for the overlap
300effects of using combination ART. However, it should be noted that 79% (n=1231) of the participants had
301exposure to only one ART core drug class for ≥ 90 days during follow-up, and associations between the
302specific NRTIs and obesity were not observed. In addition, of the six individuals who took an INSTI as
303their most-used ART core drug and developed obesity, five (83%) had no exposure to an NNRTI- or PI-
304based regimen for ≥ 90 days. Finally, due to the years of study follow-up included, overall low numbers of
305participants had INSTI exposure. However, this also makes the effect size and statistical significance

306more striking. Additionally, of the participants who took an INSTI as their most-used ART core drug,
30792.9% (n=13) used raltegravir. Thus, it is unknown whether our results will be applicable to the more
308recent generations of INSTIs.

309 A major strength of this study is the high number of female and TW participants, which allowed
310for the determination of sex/gender-specific risk factors. Other strengths included the diversity of the
311cohort in terms of race and education, the high median follow-up time and the number of years that the
312study spanned.

313**Conclusions**

314Obesity is a major concern in the HIV-infected population before and after ART initiation. Both the
315prevalence of obesity in HIV-infected, ART-naive individuals and the incidence of obesity after ART
316initiation continue to increase. Obesity prevention should be discussed at the time of ART initiation in
317order to reduce incidence and minimize long-term sequelae. Further research with a larger number of
318INSTI-exposed individuals is needed in order to validate the association between INSTIs and obesity and
319to elucidate potential mechanisms of weight gain in INSTI-treated individuals.

320

321**Acknowledgements**

322We would like to thank the INI/FIOCRUZ staff for their dedication to patient care and to maintaining the
323clinical database. In addition, we would like to thank the patients of the INI cohort for allowing this
324research to be possible. This data was previously published as an abstract at ID week 2017 (abstract
325number 1684).

326

327**Funding**

328This work was supported by the South American Program in HIV Prevention Research, National
329Institutes of Health/National Institute of Mental Health (R25 H087222 to D.B.); National Institute of
330Allergy & Infectious Diseases (K23 AI110532 to J.E.L.); National Institutes of Health (R25 MH087222
331to J.L.C.); and the National Institutes of Health funded Caribbean, Central and South America network for

332HIV epidemiology (CCASAnet), a member cohort of the International Epidemiologic Databases to

333Evaluate AIDS (leDEA) (U01AI069923).

334

335Transparency declarations

336None to declare.

337

338References

3391. Samji H, Cescon A, Hogg RS, *et al.* Closing the Gap: Increases in Life Expectancy among Treated

340HIV-Positive Individuals in the United States and Canada Okulicz JF, ed. *PLoS ONE* 2013; **8**: e81355.

3412. Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time: *Curr Opin HIV AIDS*

3422009; **4**: 194–9.

3433. Rodger AJ, Lodwick R, Schechter M, *et al.* Mortality in well controlled HIV in the continuous

344antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population: *AIDS*

3452013; **27**: 973–9.

3464. Ezechi LO, Musa ZA, Otobo VO, Idigbe IE, Ezechi OC. Trends and risk factors for obesity among

347HIV positive Nigerians on antiretroviral therapy. *Ceylon Med J* 2016; **61**: 56.

3485. Guehi C, Badjé A, Gabillard D, *et al.* High prevalence of being Overweight and Obese HIV-infected

349persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial. *AIDS Res Ther*

3502016; **13**: 12.

3516. Koethe JR, Jenkins CA, Lau B, *et al.* Rising Obesity Prevalence and Weight Gain Among Adults

352Starting Antiretroviral Therapy in the United States and Canada. *AIDS Res Hum Retroviruses* 2016; **32**:

35350–8.

3547. Amorosa V, Synnestvedt M, Gross R, *et al.* A tale of 2 epidemics: the intersection between obesity and

355HIV infection in Philadelphia. *JAIDS J Acquir Immune Defic Syndr* 2005; **39**: 557–61.

3568. Gomes A, Reyes EV, Garduno LS, *et al.* Incidence of Diabetes Mellitus and Obesity and the Overlap of
357Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy Landay A, ed. *PLOS ONE* 2016; **11**:
358e0160797.

3599. Lake JE, Stanley TL, Apovian CM, *et al.* Practical Review of Recognition and Management of Obesity
360and Lipohypertrophy in Human Immunodeficiency Virus Infection. *Clin Infect Dis Off Publ Infect Dis*
361*Soc Am* 2017; **64**: 1422–9.

36210. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-
363morbidities related to obesity and overweight: a systematic review and meta-analysis. *BMC Public Health*
3642009; **9**: 88.

36511. Wilson PWF, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as
366determinants of cardiovascular risk: the Framingham experience. *Arch Intern Med* 2002; **162**: 1867–72.

36712. Berrahmoune H, Herbeth B, Samara A, Marteau JB, Siest G, Visvikis-Siest S. Five-year alterations in
368BMI are associated with clustering of changes in cardiovascular risk factors in a gender-dependant way:
369the Stanislas study. *Int J Obes* 2008; **32**: 1279.

37013. Poirier P, Eckel RH. Obesity and cardiovascular disease. *Curr Atheroscler Rep* 2002; **4**: 448–453.

37114. Paisible A-L, Chang C-CH, So-Armah KA, *et al.* HIV Infection, Cardiovascular Disease Risk Factor
372Profile, and Risk for Acute Myocardial Infarction: *JAIDS J Acquir Immune Defic Syndr* 2015; **68**: 209–
37316.

37415. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased Acute Myocardial Infarction Rates and
375Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease. *J Clin*
376*Endocrinol Metab* 2007; **92**: 2506–12.

37716. Crum-Cianflone N, Dilay A, Collins G, *et al.* Nonalcoholic Fatty Liver Disease Among HIV-Infected
378Persons: *JAIDS J Acquir Immune Defic Syndr* 2009; **50**: 464–73.

37917. Lakey W, Yang L-Y, Yancy W, Chow S-C, Hicks C. Short Communication: From Wasting to Obesity: Initial Antiretroviral Therapy and Weight Gain in HIV-Infected Persons. *AIDS Res Hum Retroviruses* 2013; **29**: 435–40.

38218. Crum-Cianflone N, Roediger MP, Eberly L, *et al*. Increasing Rates of Obesity among HIV-Infected Persons during the HIV Epidemic Loutfy MR, ed. *PLoS ONE* 2010; **5**: e10106.

38419. McComsey GA, Moser C, Currier J, *et al*. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. *Clin Infect Dis* 2016; **62**: 853–62.

38620. Grinsztejn B, Veloso VG, Friedman RK, *et al*. Early mortality and cause of deaths in patients using HAART in Brazil and the United States: *AIDS* 2009; **23**: 2107–14.

38821. Buehler MD, Berkelman MRL. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep* 1990.

39022. Torres TS, Luz PM, Derrico M, *et al*. Factors Associated with Tobacco Smoking and Cessation among HIV-Infected Individuals under Care in Rio de Janeiro, Brazil Kumar A, ed. *PLoS ONE* 2014; **9**: e115900.

39223. Shepherd BE, Rebeiro PF, Caribbean, Central and South America network for HIV epidemiology. Brief Report: Assessing and Interpreting the Association Between Continuous Covariates and Outcomes in Observational Studies of HIV Using Splines. *J Acquir Immune Defic Syndr* 1999 2017; **74**: e60–3.

39524. World Health Organization. *Global status report on noncommunicable diseases 2014: attaining the nine global noncommunicable diseases targets; a shared responsibility*. Geneva: World Health Organization; 2014. Available at: <http://www.who.int/nmh/publications/ncd-status-report-2014/en/>.

39825. Thompson MA, Aberg JA, Hoy JF, *et al*. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. *JAMA* 2012; **308**: 387–402.

40026. World Health Organization. Clinical guidance across the continuum of care: antiretroviral therapy. *Consolidated Guidelines for the Use of Antiretroviral Drugs to Treat and Prevent HIV Infection* 2013: 90–154. Available at: <http://www.who.int/hiv/pub/guidelines/arv2013/art/en/>.

40327. Ministerio da Saude. *VIGITEL Brasil 2014: Vigilância de Fatores de Risco e Proteção para Doenças Crônicas por Inquérito Telefônico*. 2014.

40528. Menard A, Meddeb L, Tissot-Dupont H, *et al*. Dolutegravir and weight gain: an unexpected bothering side effect? *AIDS* 2017; **31**: 1499–500.

40729. Norwood J, Turner M, Bofill C, *et al*. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens. *JAIDS J Acquir Immune Defic Syndr* 2017; **76**: 527–531.

41030. Lennox JL, DeJesus E, Lazzarin A, *et al*. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. *Lancet Lond Engl* 2009; **374**: 796–806.

41331. Mulligan K, Tai VW, Schambelan M. Energy expenditure in human immunodeficiency virus infection. *N Engl J Med* 1997; **336**: 70–1.

41532. Patterson KB, Prince HA, Stevens T, *et al*. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. *AIDS Lond Engl* 2013; **27**: 1413–9.

Table 1. Study Population Characteristics at ART Initiation by Baseline BMI Category, INI/FIOCRUZ, 2000-2015.

	Underweight ($<18.5\text{kg/m}^2$) n=251 (14.0%)	Normal Weight ($18.5\text{-}24.9\text{kg/m}^2$) n=1012 (56.4%)	Overweight ($25\text{-}29.9\text{kg/m}^2$) N=390 (21.7%)	Obese ($\geq 30\text{kg/m}^2$) n=141 (7.9%)	Total n=1794	P value
Age ART Initiation (years)						
median (IQR)	34.0 (27.9,43.2)	35.7 (29.0,43.7)	37.4 (31.5,44.8)	39.8 (33.2,44.7)	36.3 (29.5,44.1)	< 0.0001
<30	86 (34.3%)	290 (28.7%)	79 (20.3%)	22 (15.6%)	477 (26.6%)	< 0.0001
30-39	84 (33.5%)	361 (35.7%)	143 (36.7%)	50 (35.5%)	638 (35.6%)	
40-49	55 (21.9%)	251 (24.8%)	114 (29.2%)	55 (39.0%)	475 (26.5%)	
≥ 50	26 (10.4%)	110 (10.9%)	54 (13.8%)	14 (9.9%)	204 (11.4%)	
Sex Category						0.0009
Male	149 (59.4%)	648 (64.0%)	243 (62.3%)	60 (42.6%)	1100 (61.3%)	
Female	81 (32.3%)	241 (23.8%)	102 (26.2%)	67 (47.5%)	491 (27.4%)	
Transgender Women	21 (8.4%)	123 (12.2%)	45 (11.5%)	14 (9.9%)	203 (11.3%)	
Race/skin color						0.0002
White	90 (35.9%)	489 (48.3%)	224 (57.4%)	63 (44.7%)	866 (48.3%)	
Black	69 (27.5%)	194 (19.2%)	56 (14.4%)	33 (23.4%)	352 (19.6%)	
Mixed/Other	92 (36.7%)	329 (32.5%)	110 (28.2%)	45 (31.9%)	576 (32.1%)	
Education level						< 0.0001
0-8 years	177 (70.5%)	505 (49.9%)	148 (37.9%)	73 (51.8%)	903 (50.3%)	
>8 years	74 (29.5%)	507 (50.1%)	242 (62.1%)	68 (48.2%)	891 (49.7%)	
Year ART Initiation						< 0.0001
2000-2003	34 (13.5%)	128 (12.6%)	33 (8.5%)	10 (7.1%)	205 (11.4%)	
2004-2007	33 (13.1%)	217 (21.4%)	69 (17.7%)	21 (14.9%)	340 (19.0%)	
2008-2011	114 (45.4%)	400 (39.5%)	157 (40.3%)	46 (32.6%)	717 (40.0%)	
2012-2015	70 (27.9%)	267 (26.4%)	131 (33.6%)	64 (45.4%)	532 (29.7%)	
CD4 ⁺ T lymphocyte count (cells/mm ³)						
median (IQR)	88 (29,207)	212 (71,334)	292 (185,400)	323 (224,439)	226 (79,350)	< 0.0001
< 100	117 (46.6%)	291 (28.8%)	57 (14.6%)	13 (9.2%)	478 (26.6%)	< 0.0001
100-249	62 (24.7%)	261 (25.8%)	93 (23.8%)	29 (20.6%)	445 (24.8%)	
250-500	31 (12.4%)	316 (31.2%)	160 (41.0%)	69 (48.9%)	576 (32.1%)	
>500	9 (3.6%)	77 (7.6%)	61 (15.6%)	23 (16.3%)	170 (9.5%)	
Missing	32 (12.7%)	67 (6.6%)	19 (4.9%)	7 (5.0%)	125 (7.0%)	
Viral Load (copies/mL)						
median log ₁₀ (IQR)	5.2 (4.5,5.7)	4.8 (4.1,5.4)	4.4 (3.8,5.2)	4.4 (3.7,5.0)	4.8 (4.0,5.4)	< 0.0001
< 100,000	88 (35.1%)	505 (49.9%)	247 (63.3%)	94 (66.7%)	934 (52.1%)	< 0.0001
$\geq 100,000$	117 (46.6%)	372 (36.8%)	105 (26.9%)	37 (26.2%)	631 (35.2%)	
Missing	46 (18.3%)	135 (13.3%)	38 (9.7%)	10 (7.1%)	229 (12.8%)	
Median Years from HIV diagnosis to ART start (IQR)	0.3 (0.1,1.0)	0.5 (0.2,2.2)	1.7 (0.4,4.2)	1.7 (0.6,5.0)	0.6 (0.2,2.7)	< 0.0001
History of Hypertension	17 (6.8%)	94 (9.3%)	74 (19%)	46 (32.6%)	231 (12.9%)	< 0.0001
History of Diabetes	14 (5.6%)	38 (3.8%)	20 (5.1%)	16 (11.3%)	88 (4.9%)	0.0013
History of Dyslipidemia	53 (21.1%)	247 (24.4%)	126 (32.3%)	58 (41.1%)	484 (27.0%)	< 0.0001
History of AIDS-defining illness	180 (71.7%)	425 (42.0%)	72 (18.5%)	19 (13.5%)	696 (38.8%)	< 0.0001
Ever smoker	137 (54.6%)	524 (51.8%)	189 (48.5%)	65 (46.1%)	915 (51.0%)	0.2733

Table 3. Factors Associated with the Development of Obesity in HIV-Infected Individuals on ART

	Remained Non-Obese (BMI < 30kg/m ²) n=1281 (81.7%)	Developed Obesity (BMI ≥ 30kg/m ²) n=286 (18.3%)	Total n=1567	Crude Hazard Ratio (95% CI)		
Follow Up Time, median years (IQR)	4.7 (2.5,7.4)	1.9 (0.9,3.6)	4.1 (2.1,7.0)			
Age ART Initiation						P value
median (IQR)	35.7 (29.0,43.8)	36.5 (30.9,43.5)	36.0 (29.3,43.8)	1.02 ^b (0.91, 1.15)		< 0.0001
<30	365 (28.5%)	64 (22.4%)	429 (27.4%)		%)	
30-39	450 (35.1%)	114 (39.9%)	564 (36.0%)		9%)	
40-49	325 (25.4%)	75 (26.2%)	400 (25.5%)		2%)	
≥ 50	141 (11.0%)	33 (11.5%)	174 (11.1%)		3%)	
Sex Category					.9,24.9)	< 0.0001
Male	815 (63.6%)	163 (57.0%)	978 (62.4%)	Ref	.9,28.1)	< 0.0001
Female	307 (24.0%)	99 (34.6%)	406 (25.9%)	1.48 (1.15, 1.90)	1.0)	0.0039
Transgender Women	159 (12.4%)	24 (8.4%)	183 (11.7%)	0.80 (0.52, 1.23)	.3, 41.9)	< 0.0001*
Race/skin color					.6, 40.2)	< 0.0001*
White	633 (49.4%)	140 (49.0%)	773 (49.3%)	Ref	.9, 60.6)	< 0.0001*
Black	241 (18.8%)	57 (19.9%)	298 (19.0%)	1.27 (0.93, 1.73)	.1, 38.0)	< 0.0001*
Mixed/Other	407 (31.8%)	89 (31.1%)	496 (31.7%)	1.12 (0.86, 1.46)		
Education level						
0-8 years	626 (48.9%)	155 (54.2%)	781 (49.8%)	Ref		
>8 years	655 (51.1%)	131 (45.8%)	786 (50.2%)	0.94 (0.74, 1.18)		
Baseline BMI (kg/m ²)						
median (IQR) ^a	21.8 (19.4,24.0)	25.3 (22.3,27.7)	22.3 (19.9,24.9)	1.15 (1.04, 1.28)		
Underweight (< 18.5)	217 (16.9%)	6 (2.1%)	223 (14.2%)			
Normal Weight (18.5-24.9)	839 (65.5%)	130 (45.5%)	969 (61.8%)			
Overweight (25-29.9)	225 (17.6%)	150 (52.4%)	375 (23.9%)			
Baseline CD4 ⁺ T lymphocyte count (cells/mm ³)						
Median (IQR) ^a *	233 (90,355)	152 (48,287)	222 (78,343)	0.74 ^c (0.61, 0.90)		
< 100	319 (24.9%)	102 (35.7%)	421 (26.9%)			
100-249	331 (25.8%)	72 (25.2%)	403 (25.7%)			
250-500	428 (33.4%)	68 (23.8%)	496 (31.7%)			
>500	122 (9.5%)	16 (5.6%)	138 (8.8%)			
Missing	81 (6.3%)	28 (9.8%)	109 (7.0%)			
Baseline Viral Load (copies/mL)						
median log ₁₀ (IQR)*	4.8 (4.0,5.4)	5.0 (4.2,5.5)	4.8 (4.1,5.4)	1.09 (0.96, 1.23)		
< 100,000	681 (53.2%)	119 (41.6%)	800 (51.1%)			
≥ 100,000	452 (35.3%)	115 (40.2%)	567 (36.2%)			
Missing	148 (11.6%)	52 (18.2%)	200 (12.8%)			
Median Years from HIV diagnosis to ART start (IQR)	0.6 (0.2,2.5)	0.5 (0.2,2.3)	0.6 (0.2,2.5)	0.98 (0.94, 1.02)		
Most-Used NRTI						
TDF	767 (59.9%)	147 (51.4%)	914 (58.3%)	Ref		
AZT	514 (40.1%)	139 (48.6%)	653 (41.7%)	0.86 (0.68, 1.09)		
Most-Used ART Core Drug Class						
NNRTI	858 (67.0%)	180 (62.9%)	1038 (66.2%)	Ref		
PI	415 (32.4%)	100 (35.0%)	515 (32.9%)	1.04 (0.82, 1.33)		
INSTI	8 (0.6%)	6 (2.1%)	14 (0.9%)	8.57 (3.77, 19.47)		
History of Hypertension	121 (9.4%)	52 (18.2%)	173 (11.0%)	1.92 (1.42, 2.60)		
History of Diabetes	47 (3.7%)	16 (5.6%)	63 (4.0%)	1.74 (1.05, 2.88)		
History of Dyslipidemia	329 (25.7%)	70 (24.5%)	399 (25.5%)	1.03 (0.78, 1.34)		
History of AIDS defining illness	489 (38.2%)	125 (43.7%)	614 (39.2%)	1.11 (0.88, 1.40)		
Ever smoker	676 (52.8%)	145 (50.7%)	821 (52.4%)	0.84 (0.66, 1.06)		

Abbreviations: *CI* confidence interval, *TDF* tenofovir, *AZT* zidovudine, *INSTI* integrase strand transfer inhibitor.


^a variable included in model using restricted cubic spline

^b crude HR per 10 year increase in age

^c crude HR per 100 cell increase in CD4⁺ T lymphocyte count

*missing values imputed in the models

419 **Figure 1. Study Participant Flowchart**






420

421 Abbreviations: *INI* Instituto Nacional de Infectologia Evandro Chagas, *INSTI* integrase strand transfer inhibitor.

422

423 **Figure 2. Factors Associated with Incident Obesity after Multivariable Analysis**



424

425 Note: date of ART initiation and end of follow-up date were accounted for in multivariable analysis.

426 Abbreviations: *AZT* zidovudine, *TDF* tenofovir, *INSTI* integrase strand transfer inhibitor, *aHR* adjusted hazard ratio,

427 *CI* confidence interval.

428 *missing values imputed in the models.

429 **variables included in the models using restricted cubic splines.